DK2442107T3 - Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse - Google Patents

Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse

Info

Publication number
DK2442107T3
DK2442107T3 DK12150646.3T DK12150646T DK2442107T3 DK 2442107 T3 DK2442107 T3 DK 2442107T3 DK 12150646 T DK12150646 T DK 12150646T DK 2442107 T3 DK2442107 T3 DK 2442107T3
Authority
DK
Denmark
Prior art keywords
haptenes
compositions
processes
preparation
hapten conjugates
Prior art date
Application number
DK12150646.3T
Other languages
English (en)
Inventor
Jerry W Kosmeder
Donald Johnson
Michael Farrell
Christopher Bieniarz
Zhanna Zhilina
Mark Lefever
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of DK2442107T3 publication Critical patent/DK2442107T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/76—Sulfur atoms attached to a second hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
DK12150646.3T 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse DK2442107T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85613306P 2006-11-01 2006-11-01
EP07867341.5A EP2078197B1 (en) 2006-11-01 2007-11-01 Haptens, hapten conjugates, compositions thereof and method for their preparation and use

Publications (1)

Publication Number Publication Date
DK2442107T3 true DK2442107T3 (da) 2014-05-19

Family

ID=39430271

Family Applications (7)

Application Number Title Priority Date Filing Date
DK12151524.1T DK2444807T3 (da) 2006-11-01 2007-11-01 Mono- og dinitropyrazolhaptenkonjugater
DK19178774.6T DK3564674T3 (da) 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til fremstilling og anvendelse deraf
DK12150646.3T DK2442107T3 (da) 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
DK07867341.5T DK2078197T3 (da) 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
DK17192133T DK3276349T3 (da) 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåder til fremstilling og anvendelse deraf
DK16151995.4T DK3029461T3 (da) 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
DK12151520.9T DK2444806T3 (da) 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK12151524.1T DK2444807T3 (da) 2006-11-01 2007-11-01 Mono- og dinitropyrazolhaptenkonjugater
DK19178774.6T DK3564674T3 (da) 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til fremstilling og anvendelse deraf

Family Applications After (4)

Application Number Title Priority Date Filing Date
DK07867341.5T DK2078197T3 (da) 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
DK17192133T DK3276349T3 (da) 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåder til fremstilling og anvendelse deraf
DK16151995.4T DK3029461T3 (da) 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
DK12151520.9T DK2444806T3 (da) 2006-11-01 2007-11-01 Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse

Country Status (8)

Country Link
US (5) US7695929B2 (da)
EP (7) EP3029461B1 (da)
JP (6) JP5576120B2 (da)
AU (1) AU2007322261B2 (da)
CA (5) CA2858359C (da)
DK (7) DK2444807T3 (da)
ES (7) ES2761949T3 (da)
WO (1) WO2008063378A2 (da)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2445826C (en) 2001-05-02 2014-03-25 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
EP1940473A2 (en) 2005-09-23 2008-07-09 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
WO2007050811A2 (en) * 2005-10-27 2007-05-03 The President And Fellows Of Harvard College Methods and compositions for labeling nucleic acids
JP5576120B2 (ja) * 2006-11-01 2014-08-20 ベンタナ・メデイカル・システムズ・インコーポレーテツド ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
US7682789B2 (en) * 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
DK2167963T3 (da) 2007-05-23 2019-06-24 Ventana Med Syst Inc Polymerbærere til immunhistokemi og in situ-hybridisering
WO2008148001A2 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
ES2557594T3 (es) 2008-06-05 2016-01-27 Ventana Medical Systems, Inc. Método para el procesamiento histoquímico y el uso de una composición para el procesamiento histoquímico
WO2010022332A1 (en) 2008-08-22 2010-02-25 Ventana Medical Systems, Inc. Method for chromogenic detection of two or more target molecules in a single sample
AU2010226392B9 (en) 2009-03-20 2014-05-22 Amgen Inc. Selective and potent peptide inhibitors of Kv1.3
JP6059533B2 (ja) 2009-11-09 2017-01-11 ユニバーシティ オブ ワシントン センター フォー コマーシャライゼーション 官能化発色性ポリマードットおよびその生物共役体
USPP22463P3 (en) * 2010-02-16 2012-01-17 Menachem Bornstein Gypsophila plant named ‘Pearl Blossom’
DK2539355T3 (da) 2010-02-26 2017-01-02 Ventana Med Syst Inc IN-SITU-hybridisering med polytag-prober
US10539487B2 (en) 2010-03-04 2020-01-21 Ventana Medical Systems, Inc. Systems and methods for monitoring tissue sample processing
US10126216B2 (en) 2011-02-17 2018-11-13 Ventana Medical Systems, Inc. Method for tissue sample fixation
AU2011222501B2 (en) 2010-03-04 2014-05-01 Ventana Medical Systems, Inc. Processing system for processing specimens using acoustic energy
AU2011242766B2 (en) 2010-04-20 2015-01-15 Ventana Medical Systems, Inc. Two-color chromogenic in situ hybridization
PT3108886T (pt) 2010-04-21 2020-08-27 Syntarga Bv Conjugados de analógicos cc-1065 e ligantes bifuncionais
CA2792569C (en) 2010-04-27 2019-01-15 Ventana Medical Systems, Inc. Antibody-nanoparticle conjugates and methods for making and using such conjugates
WO2012003478A2 (en) 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Detecting targets using mass tags and mass spectrometry
US20130109019A1 (en) * 2010-07-02 2013-05-02 Adrian E. Murillo Hapten conjugates for target detection
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
DK2606055T3 (da) 2010-08-16 2015-09-07 Ventana Med Syst Inc Substrater til chromogen påvisning og fremgangsmåder til anvendelse i påvisningsassays og -kits
CA2814780C (en) 2010-09-22 2017-05-16 Amgen Inc. Carrier immunoglobulins and uses thereof
AU2011317142B2 (en) 2010-10-18 2015-04-23 University of Washington Center for Commercialization Chromophoric polymer dots
MX350974B (es) * 2010-11-18 2017-09-27 Univ Yale Moleculas bifuncionales con actividad reclutadora de anticuerpos e inhibidora de la entrada frente al virus de inmunodeficiencia humana.
WO2012123387A1 (en) 2011-03-14 2012-09-20 F. Hoffmann-La Roche Ag A method of analyzing chromosomal translocations and a system therefore
US9797840B2 (en) 2011-11-28 2017-10-24 University Of Washington Through Its Center For Commercialization Highly fluorescent polymer nanoparticle
WO2013079606A1 (en) 2011-12-01 2013-06-06 Ventana Medical Systems, Inc. Automated dual stain of mirna and protein targets
WO2013101902A2 (en) 2011-12-30 2013-07-04 University Of Washington, Through Its Center For Commercialization Chromophoric polymer dots with narrow-band emission
WO2013108126A2 (en) 2012-01-16 2013-07-25 University Of Oslo Methyltransferases and uses thereof
AU2013211666B2 (en) 2012-01-23 2015-09-03 Ventana Medical Systems, Inc Polymer stabilization of chromogen solutions
WO2013116614A1 (en) 2012-02-03 2013-08-08 University Of Washington Through Its Center For Commercialization Polyelectrolyte-coated polymer dots and related methods
JP6101782B2 (ja) * 2012-03-27 2017-03-22 ヴェンタナ メディカル システムズ， インク． シグナリングコンジュゲート及び使用法
US9123538B2 (en) * 2012-04-26 2015-09-01 Regents Of The University Of Minnesota Silicon nanocrystal inks, films, and methods
CN102654500A (zh) * 2012-05-17 2012-09-05 重庆市科学技术研究院 一种检测喹噁啉-2-羧酸的检测试剂盒及其方法
PT3663317T (pt) * 2012-08-21 2023-01-23 Janssen Pharmaceutica Nv Anticorpos para haptenos de quetiapina e sua utilização
WO2014139979A1 (en) 2013-03-12 2014-09-18 Ventana Medical Systems, Inc. Quantum dot in situ hybridization
US9663814B2 (en) 2013-03-12 2017-05-30 Ventana Medical Systems, Inc. Proximity assay for in situ detection of targets
JP6223538B2 (ja) 2013-03-12 2017-11-01 ベンタナ メディカル システムズ， インコーポレイテッド 多重化組織用のデジタル的に強化された顕微鏡
EP2972349B1 (en) 2013-03-14 2019-10-23 University Of Washington Through Its Center For Commercialization Polymer dot compositions and related methods
EP3063291B1 (en) * 2013-10-11 2019-03-20 Ventana Medical Systems, Inc. Multiplex her2 and estrogen receptor co-staining assays for detecting tumor heterogeneity
ES2742308T3 (es) 2013-10-24 2020-02-13 Siemens Healthcare Diagnostics Inc Ensayos de analitos macromoleculares
CN105899237B (zh) 2014-01-10 2019-09-03 斯索恩生物制药有限公司 用于治疗子宫内膜癌的倍癌霉素adc
CA2935433C (en) 2014-01-10 2019-04-02 Synthon Biopharmaceuticals B.V. Duocarmycin anti-her2 antibody drug conjucates with activity against her2 expressing malignancies
EP3111224B1 (en) 2014-02-24 2018-12-26 Ventana Medical Systems, Inc. Quinone methide analog signal amplification
CA2940118C (en) 2014-02-24 2023-05-23 Ventana Medical Systems, Inc. Automated rna detection using labeled 2'-o-methyl rna oligonucleotide probes and signal amplification systems
JP6626097B2 (ja) 2014-06-06 2019-12-25 ヴェンタナ メディカル システムズ， インク． 乳がんにおける腫瘍内ｈｅｒ２不均質性の意義及びそのための使用
US20170320965A1 (en) * 2014-09-22 2017-11-09 Synthon Biopharmaceuticals B.V. Pan-reactive antibodies to duocarmycins
WO2016050913A2 (en) 2014-10-02 2016-04-07 Ventana Medical Systems, Inc. Polymers and conjugates comprising the same
JP6909156B2 (ja) 2014-11-25 2021-07-28 ヴェンタナ メディカル システムズ， インク． 化学ライゲーション及びハプテン移行を用いた近接アッセイ
WO2016087589A1 (en) 2014-12-03 2016-06-09 Ventana Medical Systems, Inc. Methods, systems, and apparatuses for quantitative analysis of heterogeneous biomarker distribution
IL282614B2 (en) 2015-02-06 2024-02-01 Cell Idx Inc Antigen-conjugated immune reagents
ES2939352T3 (es) 2015-04-13 2023-04-21 Ventana Med Syst Inc Procedimientos y sistemas de inactivación de anticuerpo con base termoquímica
JP6720208B2 (ja) 2015-04-17 2020-07-08 スプリング バイオサイエンス コーポレーション Ｃ４．４ａを検出するための抗体、組成物、及び免疫組織化学法
WO2016190236A1 (ja) * 2015-05-28 2016-12-01 コニカミノルタ株式会社 インサイチュハイブリダイゼイション用のプローブ試薬
CN105018072B (zh) * 2015-07-08 2017-02-01 山东理工大学 检测人血清白蛋白的荧光探针及其制备方法
CA2996798A1 (en) 2015-08-28 2017-03-09 Ventana Medical Systems, Inc. Protein proximity assay in formalin fixed paffafin embedded tissue using caged haptens
MX2018004838A (es) 2015-11-06 2019-07-18 Ventana Med Syst Inc Diagnosticos representativos.
AU2017229370B2 (en) 2016-03-08 2021-03-11 Ventana Medical Systems, Inc. Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
CN116840465A (zh) 2016-06-28 2023-10-03 文塔纳医疗系统公司 用多染料醌甲基化物和酪酰胺缀合物的显色ihc和ish染色的新颜色
JP7128121B2 (ja) 2016-06-28 2022-08-30 ヴェンタナ メディカル システムズ， インク． Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
EP3485275A4 (en) * 2016-07-18 2020-06-17 Cell IDX, Inc. ANTIGEN-COUPLED HYBRIDIZATION REAGENTS
EP3515449B1 (en) * 2016-09-26 2023-07-12 Dana-Farber Cancer Institute, Inc. Quinoline derivatives as chromobox (cbx) protein inhibitors for treating cancer
EP3929304B1 (en) * 2016-12-16 2024-02-21 Aratome LLC Molecular detection using ligation amplification
EP4220164A3 (en) 2016-12-19 2023-08-09 Ventana Medical Systems, Inc. Methods and systems for quantitative immunohistochemistry
JP7048617B2 (ja) 2016-12-19 2022-04-05 ヴェンタナ メディカル システムズ， インク． ペプチド核酸コンジュゲート
EP3568157A4 (en) * 2017-01-13 2021-01-06 National Research Council of Canada METHOD FOR OPTIMIZING THE PEPTIDE IMMUNO-EPITOP BY GLYCOSYLATION, OPTIMIZED PEPTIDE THEREOF AND ITS USE FOR CONJUGATE VACCINES
EP3601339A4 (en) 2017-03-31 2020-11-04 Ultivue, Inc. DNA ANTIGEN EXCHANGE AND AMPLIFICATION
US10768185B2 (en) * 2017-07-20 2020-09-08 Trustees Of Boston University Tenofovir detection assay
WO2019120635A1 (en) 2017-12-18 2019-06-27 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
US10330684B1 (en) 2018-04-05 2019-06-25 Rarecyte, Inc. Analyte detection
WO2019194994A1 (en) * 2018-04-05 2019-10-10 Rarecyte, Inc. Analyte detection
EP3797296A1 (en) 2018-05-21 2021-03-31 Genentech, Inc. Her2 heterogeneity as a biomarker in cancer
EP3853214A1 (en) * 2018-09-20 2021-07-28 Ventana Medical Systems, Inc. Coumarin-based crosslinking reagents
EP3969876A1 (en) 2019-05-14 2022-03-23 Ventana Medical Systems, Inc. System including a biological sample treatment chamber
CN110330488A (zh) * 2019-06-20 2019-10-15 深圳市易瑞生物技术股份有限公司 一种吡罗昔康半抗原及其制备方法和应用
CN114829368A (zh) 2019-12-18 2022-07-29 豪夫迈·罗氏有限公司 通过使用连续标记方案的合成进行测序的方法
US11814677B2 (en) * 2019-12-30 2023-11-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods and systems for sensitive and multiplexed analysis of biological samples using cleavable fluorescent streptavidin and anti-hapten antibodies
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
EP4147054A1 (en) 2020-05-07 2023-03-15 Ventana Medical Systems, Inc. Histochemical systems and methods for evaluating egfr and egfr ligand expression in tumor samples
KR102506288B1 (ko) * 2020-09-07 2023-03-06 국립암센터 디그옥시제닌에 대한 항체를 포함하는 복합체, 및 이들의 용도
CN112362863B (zh) * 2020-11-02 2024-02-13 上海市农业科学院 一种巯基功能化脂质体纳米材料及其制备方法和应用
JP2024504944A (ja) 2021-01-15 2024-02-02 ヴェンタナ メディカル システムズ， インク． 保存安定なケージドハプテン
JP2024507677A (ja) 2021-01-25 2024-02-21 ベンタナ メディカル システムズ， インコーポレイテッド １つ又は複数の検出可能部分で標識された１つ又は複数のバイオマーカーを含む染色された生物学的検体
EP4326736A1 (en) 2021-04-18 2024-02-28 Ventana Medical Systems, Inc. Morphological marker staining
WO2022240641A1 (en) * 2021-05-12 2022-11-17 The Scripps Research Institute High-throughput assay for identification of myc inhibitors
WO2023205669A2 (en) * 2022-04-19 2023-10-26 Purdue Research Foundation Dual and triple hapten conjugates, compositions, processes for making, and methods of treatment therewith
WO2023232829A1 (en) * 2022-05-31 2023-12-07 Illumina, Inc Compositions and methods for nucleic acid sequencing
WO2024002924A2 (en) 2022-06-28 2024-01-04 F. Hoffmann-La Roche Ag Fluorescent dyes with large stokes shift

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892530A (en) * 1974-09-23 1975-07-01 Hoffmann La Roche Colorimetric and fluorometric method
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4230683A (en) * 1978-08-09 1980-10-28 Abbott Laboratories Hapten conjugated antibody for antibody or antigen detection
US4223013A (en) * 1978-12-29 1980-09-16 Syva Company Amitriptyline conjugates to antigenic proteins and enzymes
US4495296A (en) * 1979-05-21 1985-01-22 New York Blood Center, Inc. Labeled anti-hapten antibodies and their use as a universal reagent for solid phase radio- and/or enzyme-immunoassays
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4425427A (en) * 1980-03-13 1984-01-10 Vitafin N.V. Simultaneous, kinetic, spectrophotometric analysis of blood serum for multiple components
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4490473A (en) * 1983-03-28 1984-12-25 Panab Labeled antibodies and methods
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1236641A (en) 1984-07-06 1988-05-10 Motoaki Tanaka Copolymer of lactic acid and glycolic acid and method for producing same
US4879224A (en) 1985-01-10 1989-11-07 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5756696A (en) * 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2039025T3 (es) 1987-11-16 1993-08-16 Janssen Pharmaceutica N.V. Un agregado para determinar sustancias combinables.
DE3811692A1 (de) * 1988-04-07 1989-10-19 Idt Ag Fuer In Vivo Diagnostik Diagnostikverfahren und mittel zur diagnose und behandlung immunologischer erkrankungen
CA1308022C (en) * 1988-08-11 1992-09-29 Eleftherios P. Diamandis Multiple fluorescence labelling with europium chelators
DE3836656A1 (de) 1988-10-27 1990-05-03 Boehringer Mannheim Gmbh Neue digoxigenin-derivate und ihre verwendung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5595707A (en) 1990-03-02 1997-01-21 Ventana Medical Systems, Inc. Automated biological reaction apparatus
US5225325A (en) 1990-03-02 1993-07-06 Ventana Medical Systems, Inc. Immunohistochemical staining method and reagents therefor
GB2255637B (en) * 1991-03-20 1995-11-15 Marconi Gec Ltd Separation method
WO1993020094A1 (en) * 1992-03-27 1993-10-14 Abbott Laboratories Haptens, tracers, immunogens and antibodies for quinoline
US6100099A (en) * 1994-09-06 2000-08-08 Abbott Laboratories Test strip having a diagonal array of capture spots
US5403747A (en) * 1992-04-01 1995-04-04 Thomas Jefferson University Protein assay using microwave energy
US5350686A (en) 1992-04-16 1994-09-27 Pioneer Hi-Bred International, Inc. Microwave acceleration of enzyme-catalyzed modification of macromolecules
US5834202A (en) * 1992-08-04 1998-11-10 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5393891A (en) * 1993-06-08 1995-02-28 The Du Pont Merck Pharmaceutical Company Immunoassay reagents and methods for detecting brequinar and analogs
US5679582A (en) 1993-06-21 1997-10-21 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US5661040A (en) * 1993-07-13 1997-08-26 Abbott Laboratories Fluorescent polymer labeled conjugates and intermediates
WO1995003296A1 (en) * 1993-07-20 1995-02-02 Abbott Laboratories Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives
US5731171A (en) * 1993-07-23 1998-03-24 Arch Development Corp. Sequence independent amplification of DNA
US5643761A (en) 1993-10-27 1997-07-01 The Trustees Of Columbia University In The City Of New York Method for generating a subtracted cDNA library and uses of the generated library
US5487975A (en) 1993-11-15 1996-01-30 Ventana Medical Systems, Inc. Biotin/avidin formulation
DE4407538C1 (de) * 1994-03-07 1995-02-23 Deutsches Krebsforsch Bindungsreagens für Zell-Oberflächenprotein und Effektorzelle
US5648211A (en) * 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
GB9420355D0 (en) * 1994-10-10 1994-11-23 Univ Nottingham Preparation of protein microspheres, films and coatings
US6057099A (en) * 1994-12-02 2000-05-02 Intelligene Ltd. Detection of nucleic acid sequences
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5648245A (en) * 1995-05-09 1997-07-15 Carnegie Institution Of Washington Method for constructing an oligonucleotide concatamer library by rolling circle replication
US5684142A (en) 1995-06-07 1997-11-04 Oncor, Inc. Modified nucleotides for nucleic acid labeling
US5883081A (en) * 1995-07-26 1999-03-16 The Regents Of The University Of California Isolation of novel HIV-2 proviruses
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6750016B2 (en) * 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) * 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US6506564B1 (en) * 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
JPH10104230A (ja) * 1996-09-30 1998-04-24 Aisin Seiki Co Ltd 核酸等の検出方法，並びに標識物質及び検出物質
ATE230034T1 (de) * 1996-10-04 2003-01-15 Univ Heidelberg Verfahren zur aufreinigung von dns
US5952890A (en) 1997-02-05 1999-09-14 Fox Enterprises, Inc. Crystal oscillator programmable with frequency-defining parameters
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
JPH1151935A (ja) * 1997-08-06 1999-02-26 Aisin Seiki Co Ltd 複数種類のターゲット分子の同時検出方法
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
JPH11240879A (ja) * 1997-12-22 1999-09-07 Nissan Chem Ind Ltd ピラゾールスルホニルウレアのポリクローナル抗体及び検出方法
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6855559B1 (en) 1998-09-03 2005-02-15 Ventana Medical Systems, Inc. Removal of embedding media from biological samples and cell conditioning on automated staining instruments
US20030211630A1 (en) 1998-02-27 2003-11-13 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
US6582962B1 (en) 1998-02-27 2003-06-24 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
JP3847559B2 (ja) 1998-02-27 2006-11-22 ベンタナ・メデイカル・システムズ・インコーポレーテツド 独立スライド加熱器を有する自動化分子病理学装置
US6235480B1 (en) * 1998-03-13 2001-05-22 Promega Corporation Detection of nucleic acid hybrids
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6855552B2 (en) 1998-09-03 2005-02-15 Ventana Medical Systems Automated immunohistochemical and in situ hybridization assay formulations
US7550298B2 (en) 1998-09-03 2009-06-23 Ventana Medical Systems, Inc. Automated immunohistochemical and in situ hybridization assay formulations
JP2000095769A (ja) * 1998-09-22 2000-04-04 Kankyo Meneki Gijutsu Kenkyusho:Kk プロベナゾールのハプテン化合物、抗体及び測定方法
CA2345376C (en) * 1998-09-24 2010-03-16 Advanced Research And Technology Institute, Inc. Water-soluble luminescent quantum dots and bioconjugates thereof
US6414133B1 (en) 1998-10-13 2002-07-02 Ventana Medical Systems, Inc. Multiple fusion probes
US7569344B2 (en) 1998-10-26 2009-08-04 Ventana Medical Systems, Inc. Detection of human papilloma virus in papanicolaou (Pap) smears
US6432320B1 (en) 1998-11-02 2002-08-13 Patrick Bonsignore Refrigerant and heat transfer fluid additive
US6699973B1 (en) * 1998-11-19 2004-03-02 Elan Corporation, Plc Antibodies to peptides that target GIT receptors and related methods
AU2410500A (en) 1999-01-11 2000-08-01 President And Fellows Of Harvard College Isothermal amplification of dna
US6344337B1 (en) * 1999-02-19 2002-02-05 Board Of Trustees Of Michigan State University Antigen test to detect equine protozoal myeloencephalitis in horse serum and cerebrospinal fluid
US6696304B1 (en) * 1999-02-24 2004-02-24 Luminex Corporation Particulate solid phase immobilized protein quantitation
US6544798B1 (en) 1999-02-26 2003-04-08 Ventana Medical Systems, Inc. Removal of embedding media from biological samples and cell conditioning on automated staining instruments
US6673214B1 (en) * 1999-04-09 2004-01-06 Rocky Mountain Biosystems, Inc. Energy enhanced reaction catalysis and uses thereof
MXPA01010296A (es) 1999-04-13 2005-06-30 Wilex Ag Diagnostico y uso terapeutico de anticuerpos contra el receptor urocinasa.
DE60042738D1 (de) * 1999-05-07 2009-09-24 Life Technologies Corp Verfahren zum nachweis von analyten mit hilfe von halbleiternanokrystallen
US6180349B1 (en) * 1999-05-18 2001-01-30 The Regents Of The University Of California Quantitative PCR method to enumerate DNA copy number
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
DE19933701A1 (de) * 1999-07-19 2001-01-25 Wilex Biotechnology Gmbh Zyklische peptidomimetische Urokinaserezeptorantagonisten
JP2001089484A (ja) * 1999-09-22 2001-04-03 Kankyo Meneki Gijutsu Kenkyusho:Kk トリシクラゾールのハプテン化合物、抗体及び測定方法
EP1218547A4 (en) * 1999-10-15 2005-04-20 Ventana Med Syst Inc METHOD FOR DETECTING UNIQUE GENE IN SITU COPIES
US20060275784A1 (en) 1999-10-26 2006-12-07 Ventana Medical Systems, Inc. Detection of Human Papilloma Virus in Papanicolaou (Pap) Smears
US7833698B2 (en) 2000-01-12 2010-11-16 Ventana Medical Systems, Inc. Method for determining the response to cancer therapy
EP1294930B1 (en) * 2000-01-13 2011-03-30 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
EP1266223B1 (en) * 2000-03-20 2007-05-16 Massachusetts Institute of Technology Inorganic particle conjugates
JP4317913B2 (ja) 2000-04-14 2009-08-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド Ａｋｔタンパク質発現の定量方法
US6291187B1 (en) 2000-05-12 2001-09-18 Molecular Staging, Inc. Poly-primed amplification of nucleic acid sequences
US6828097B1 (en) * 2000-05-16 2004-12-07 The Childrens Mercy Hospital Single copy genomic hybridization probes and method of generating same
WO2001088089A2 (en) 2000-05-16 2001-11-22 Children's Mercy Hospital Single copy genomic hybridization probes and method of generating same
US6794362B1 (en) * 2000-05-30 2004-09-21 Connective Tissue Imagineering Llc Asparagine containing elastin peptide analogs
US7763421B2 (en) 2000-06-05 2010-07-27 Ventana Medical Systems, Inc. Methods for producing nucleic acid hybridization probes that amplify hybridization signal by promoting network formation
US6323009B1 (en) 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
US6447692B1 (en) 2000-08-04 2002-09-10 Hrl Laboratories, Llc Nanometer sized phase change materials for enhanced heat transfer fluid performance
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
US20040209303A1 (en) 2000-10-03 2004-10-21 Martin Mark T. Methods and compositions for directed microwave chemistry
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6576291B2 (en) * 2000-12-08 2003-06-10 Massachusetts Institute Of Technology Preparation of nanocrystallites
ES2312490T3 (es) * 2000-12-11 2009-03-01 President And Fellows Of Harvard College Dispositivo que contiene manosensores para detectar un analito y su metodo de fabricacion.
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US20030022166A1 (en) * 2001-01-19 2003-01-30 Colin Collins Repeat-free probes for molecular cytogenetics
US6656685B2 (en) 2001-01-29 2003-12-02 Ventana Medical Systems, Inc. Hybridization buffers using low molecular weight dextran sulfate and methods for their use
WO2003004944A2 (en) * 2001-01-30 2003-01-16 Materials And Electrochemical Research (Mer) Corporation Nano carbon materials for enhancing thermal transfer in fluids
DE10105912A1 (de) * 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Rekombinante Proteinase K
US20030003537A1 (en) 2001-04-30 2003-01-02 Ventana Medical Systems, Inc. Method and composition of matter for enhancing staining of microorganisms
EP1385999B1 (en) 2001-04-30 2012-12-12 Ventana Medical Systems, Inc. Reagents and methods for automated in situ or microarray hybridization
NZ511705A (en) * 2001-05-14 2004-03-26 Horticulture & Food Res Inst Methods and rapid immunoassay device for detecting progesterone and other steroids
WO2003000853A2 (en) * 2001-06-20 2003-01-03 Caprion Pharmaceuticals Inc. Protein aggregation assays and uses thereof
DE60234181D1 (de) * 2001-07-02 2009-12-10 Arctic Diagnostics Oy Zwei photonen absorbierende bordipyrromethen-difluorid-farbstoffe und ihre anwendungen
EP2218762A3 (en) 2001-07-20 2010-09-29 Life Technologies Corporation Luminescent nanoparticles and methods for their preparation
US20030066998A1 (en) * 2001-08-02 2003-04-10 Lee Howard Wing Hoon Quantum dots of Group IV semiconductor materials
WO2003031419A1 (en) * 2001-10-09 2003-04-17 3-Dimensional Pharmaceuticals, Inc. Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
US6617137B2 (en) 2001-10-15 2003-09-09 Molecular Staging Inc. Method of amplifying whole genomes without subjecting the genome to denaturing conditions
US6977148B2 (en) 2001-10-15 2005-12-20 Qiagen Gmbh Multiple displacement amplification
US20030165485A1 (en) 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
US7358041B2 (en) * 2001-11-30 2008-04-15 Short Mary K Antibodies to magmas and uses thereof
US20050019901A1 (en) * 2002-01-31 2005-01-27 Evgenia Matveeva Methods for synthesis of bio-active nanoparticles and nanocapsules for use in optical bio-disc assays and disc assembly including same
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
US7476442B2 (en) 2002-07-17 2009-01-13 Massachusetts Institute Of Technology Nanoparticle chains and preparation thereof
AU2003302133A1 (en) * 2002-10-25 2004-06-15 Sense Proteomic Limited Uses of ble proteins and antibiotics from the bleomycin family
US7200252B2 (en) 2002-10-28 2007-04-03 Ventana Medical Systems, Inc. Color space transformations for use in identifying objects of interest in biological specimens
US7233817B2 (en) 2002-11-01 2007-06-19 Brian Yen Apparatus and method for pattern delivery of radiation and biological characteristic analysis
US20040101822A1 (en) * 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
GB0227738D0 (en) * 2002-11-28 2003-01-08 Univ Liverpool Nanoparticle conjugates and method of production thereof
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US7056471B1 (en) * 2002-12-16 2006-06-06 Agency For Science Technology & Research Ternary and quarternary nanocrystals, processes for their production and uses thereof
WO2004094652A2 (en) 2003-04-22 2004-11-04 Neurobiotex, Inc. Zinc-based screening test and kit for early diagnosis of prostate cancer
US6944333B2 (en) 2003-04-30 2005-09-13 Ventana Medical Systems, Inc. Color image compression via spectral decorrelation and elimination of spatial redundancy
JP4740862B2 (ja) 2003-05-07 2011-08-03 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 合金化された半導体量子ドットおよび合金化された濃度勾配量子ドット、これらの量子ドットを含むシリーズ、ならびにこれらに関する方法
CA2526126C (en) 2003-05-19 2012-05-15 Ventana Medical Systems, Inc. Electrophoretic in situ tissue staining
US20050181394A1 (en) 2003-06-20 2005-08-18 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
JP4648902B2 (ja) 2003-06-24 2011-03-09 ベンタナ・メデイカル・システムズ・インコーポレーテツド 免疫組織化学的エピトープおよび核酸配列のインサイチュ検出が向上するように酵素の触媒作用で金属を付着
KR100657891B1 (ko) 2003-07-19 2006-12-14 삼성전자주식회사 반도체 나노결정 및 그 제조방법
US20050048498A1 (en) * 2003-08-29 2005-03-03 Applera Corporation Compositions, methods, and kits for assembling probes
KR100571817B1 (ko) * 2003-09-19 2006-04-17 삼성전자주식회사 태그 서열에 혼성화하는 검출 프로브를 이용하는 표적핵산의 검출방법
JP2007506429A (ja) * 2003-09-23 2007-03-22 アトム・サイエンシズ・インコーポレーテッド ポリマー核酸のハイブリダイゼーションプローブ
AU2004290017B2 (en) 2003-11-07 2012-05-03 Immunex Corporation Antibodies that bind interleukin-4 receptor
US7541455B2 (en) 2003-12-22 2009-06-02 Ventana Medical Systems, Inc. Microwave mediated synthesis of nucleic acid probes
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
US7104313B2 (en) 2003-12-31 2006-09-12 Intel Corporation Apparatus for using fluid laden with nanoparticles for application in electronic cooling
US7244665B2 (en) 2004-04-29 2007-07-17 Micron Technology, Inc. Wafer edge ring structures and methods of formation
EP1753876A2 (en) 2004-05-04 2007-02-21 Ventana Medical Systems, Inc. Internal control in situ hybridization
US20060110744A1 (en) * 2004-11-23 2006-05-25 Sampas Nicolas M Probe design methods and microarrays for comparative genomic hybridization and location analysis
US7947839B2 (en) * 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20060160116A1 (en) * 2004-12-16 2006-07-20 The Regents Of The University Of California Repetitive sequence-free DNA libraries
EP1893241A2 (en) 2005-04-28 2008-03-05 Ventana Medical Systems, Inc. Fluorescent nanoparticles conjugated to antibodies via a peg linker
US7615800B2 (en) 2005-09-14 2009-11-10 Eastman Kodak Company Quantum dot light emitting layer
CN104090095B (zh) * 2005-11-23 2016-06-01 文塔纳医疗系统公司 分子缀合物
JP4960972B2 (ja) 2005-12-30 2012-06-27 ベンタナ・メデイカル・システムズ・インコーポレーテツド 子宮頸部異形成および子宮頸癌におけるＮａ＋、Ｋ＋−ＡＴＰアーゼの発現
US8420798B2 (en) 2006-09-01 2013-04-16 Ventana Medical Systems, Inc. Method for producing nucleic acid probes
JP5576120B2 (ja) 2006-11-01 2014-08-20 ベンタナ・メデイカル・システムズ・インコーポレーテツド ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法
US7682789B2 (en) * 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
DK2167963T3 (da) * 2007-05-23 2019-06-24 Ventana Med Syst Inc Polymerbærere til immunhistokemi og in situ-hybridisering
WO2010104899A1 (en) * 2009-03-12 2010-09-16 Glaxosmithkline Llc Thiazole sulfonamide and oxazole sulfonamide kinase inhibitors

Also Published As

Publication number Publication date
JP6691092B2 (ja) 2020-04-28
AU2007322261B2 (en) 2014-01-23
CA2858359C (en) 2018-04-03
ES2761949T3 (es) 2020-05-21
CA2995467A1 (en) 2008-05-29
JP7000489B2 (ja) 2022-01-19
EP2444806A2 (en) 2012-04-25
WO2008063378A2 (en) 2008-05-29
DK3276349T3 (da) 2019-10-28
JP2013231044A (ja) 2013-11-14
EP2444807A3 (en) 2013-02-27
JP5576120B2 (ja) 2014-08-20
CA3069091A1 (en) 2008-05-29
ES2493166T3 (es) 2014-09-11
US9719986B2 (en) 2017-08-01
EP3564674A1 (en) 2019-11-06
ES2905054T3 (es) 2022-04-06
JP2020126057A (ja) 2020-08-20
CA2666234C (en) 2014-10-14
EP2078197A2 (en) 2009-07-15
ES2491743T3 (es) 2014-09-08
ES2570600T3 (es) 2016-05-19
JP6259477B2 (ja) 2018-01-10
US11092594B2 (en) 2021-08-17
US20100297725A1 (en) 2010-11-25
JP2010508532A (ja) 2010-03-18
WO2008063378A3 (en) 2008-12-04
US20180120306A1 (en) 2018-05-03
CA3125026A1 (en) 2008-05-29
US20100184087A1 (en) 2010-07-22
US20140323336A1 (en) 2014-10-30
JP5722952B2 (ja) 2015-05-27
EP2442107A3 (en) 2012-11-14
EP2444806A3 (en) 2013-02-27
EP2444807A2 (en) 2012-04-25
DK3564674T3 (da) 2021-10-18
US8846320B2 (en) 2014-09-30
JP5973524B2 (ja) 2016-08-23
WO2008063378A9 (en) 2008-07-31
CA2666234A1 (en) 2008-05-29
EP2442107B1 (en) 2014-03-12
AU2007322261A1 (en) 2008-05-29
EP3029461A1 (en) 2016-06-08
US7695929B2 (en) 2010-04-13
EP2078197B1 (en) 2016-03-23
EP3029461B1 (en) 2017-12-20
DK2078197T3 (da) 2016-05-23
JP2016136150A (ja) 2016-07-28
DK3029461T3 (da) 2018-02-05
CA2995467C (en) 2020-03-10
EP2444807B1 (en) 2014-06-11
JP2015072275A (ja) 2015-04-16
CA3069091C (en) 2021-09-14
EP2078197A4 (en) 2010-03-24
EP2444806B1 (en) 2014-05-28
JP2018040813A (ja) 2018-03-15
EP3564674B1 (en) 2021-08-25
US20080268462A1 (en) 2008-10-30
CA2858359A1 (en) 2008-05-29
DK2444806T3 (da) 2014-07-21
DK2444807T3 (da) 2014-08-11
EP2442107A2 (en) 2012-04-18
ES2663080T3 (es) 2018-04-11
CA3125026C (en) 2023-04-04
US8618265B2 (en) 2013-12-31
EP3276349A1 (en) 2018-01-31
EP3276349B1 (en) 2019-08-07
ES2465465T3 (es) 2014-06-05

Similar Documents

Publication Publication Date Title
DK2444806T3 (da) Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
FR22C1008I2 (fr) Composition immunogène
NO20201120A1 (no) Bindingsvirkninger
DK2063907T3 (da) Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater
DK3219328T3 (da) Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK1912671T3 (da) Beta-glucuronid-linker-lægemiddelkonjugater
DK1884242T3 (da) Farmaceutisk sammensætning omfattende lurasidon
DK1868645T3 (da) Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
DK2229360T3 (da) Indolinonderivater og fremgangsmåde til deres fremstilling
DK2069352T3 (da) Bestemte kemiske enheder, sammensætninger og fremgangsmåder
DE602005005527D1 (de) Verschlussdüse
DK1939204T6 (da) Kondenseret heterocyklisk derivat, medicinalsammensætning indeholdende samme og medicinsk anvendelse deraf
DK2121713T3 (da) Oligosaccharider, omfattende en aminooxygruppe, og konjugater deraf
DK1817055T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
DE602006018024D1 (de) Brennstoffzugabevorrichtung
IL193392A0 (en) Influenza antibodies, compositions, and related methods
DE602005019525D1 (de) Verschlussdüse
DE502007005744D1 (de) Schallgedämpftes, gasführendes Bauteil
DK2158199T3 (da) Piperidinforbindelser og anvendelser deraf
DK1976884T3 (da) Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.
DK2041069T3 (da) Benzylaminer, fremgangsmåde til fremstilling deraf og deres anvendelse som anti-inflammatoriske midler
DK3181691T3 (da) Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme
DK1718340T3 (da) Nye effektorkonjugater, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse